Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Lecia Vandam Sequist, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
Most Recent  |  List All
  1. R21CA156000 (SEQUIST, LECIA V.) May 1, 2011 - Apr 30, 2013
    NIH
    Repeat Biopsies in Lung Cancer to Define Targeted Resistance Mechanisms
    Role: Principal Investigator
  2. R01CA137008 (SEQUIST, LECIA V.) Mar 1, 2009 - Mar 31, 2021
    NIH
    Impact of heterogeneity on response to EGFR T790M inhibitors
    Role: Co-Principal Investigator
  3. T32CA071345 (HABER, DANIEL A.) Aug 1, 1997 - Aug 31, 2023
    NIH
    Training Program in Cancer Biology and Therapeutics
    Role: Co-Principal Investigator

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Milligan MG, Lennes IT, Hawari S, Khandekar MJ, Colson Y, Shepard JO, Frank A, Sequist LV, Willers H, Keane FK. Incidence of Radiation Therapy Among Patients Enrolled in a Multidisciplinary Pulmonary Nodule and Lung Cancer Screening Clinic. JAMA Netw Open. 2022 Mar 01; 5(3):e224840. PMID: 35357454.
    Citations:    Fields:    
  2. Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, Jänne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba II, Wolf J, Wu YL, Yang SR, Yang JCH, Yatabe Y, Pentheroudakis G, Peters S. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol. 2022 Feb 14. PMID: 35176458.
    Citations: 1     Fields:    
  3. Cooper AJ, Sequist LV, Johnson TW, Lin JJ. LTK fusions: A new target emerges in non-small cell lung cancer. Cancer Cell. 2022 01 10; 40(1):23-25. PMID: 35016028.
    Citations:    Fields:    Translation:Humans
  4. Lin JJ, Muzikansky A, Kennedy E, Kuberski H, Stober LL, Wanat AC, Azzoli CG, Lennes I, Sequist LV, Dagogo-Jack I, Shaw AT, Gainor JF. Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study. ESMO Open. 2022 02; 7(1):100342. PMID: 34896762.
    Citations:    Translation:CTClinical Trials
  5. White MN, Piper-Vallillo AJ, Gardner RM, Cunanan K, Neal JW, Das M, Padda SK, Ramchandran K, Chen TT, Sequist LV, Piotrowska Z, Wakelee HA. Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clin Lung Cancer. 2021 Nov 11. PMID: 34887193.
    Citations:    Fields:    
  6. Hu H, Piotrowska Z, Hare PJ, Chen H, Mulvey HE, Mayfield A, Noeen S, Kattermann K, Greenberg M, Williams A, Riley AK, Wilson JJ, Mao YQ, Huang RP, Banwait MK, Ho J, Crowther GS, Hariri LP, Heist RS, Kodack DP, Pinello L, Shaw AT, Mino-Kenudson M, Hata AN, Sequist LV, Benes CH, Niederst MJ, Engelman JA. Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell. 2021 11 08; 39(11):1531-1547.e10. PMID: 34624218.
    Citations: 3     Fields:    Translation:HumansCells
  7. Meador CB, Sequist LV, Piotrowska Z. Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates. Cancer Discov. 2021 09; 11(9):2145-2157. PMID: 34301786.
    Citations: 2     Fields:    
  8. Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021 08 07; 398(10299):535-554. PMID: 34273294.
    Citations: 26     Fields:    Translation:Humans
  9. Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, Bivona T, Diehn M, Dive C, Dziadziuszko R, Leighl N, Malapelle U, Mok T, Peled N, Raez LE, Sequist L, Sholl L, Swanton C, Abbosh C, Tan D, Wakelee H, Wistuba I, Bunn R, Freeman-Daily J, Wynes M, Belani C, Mitsudomi T, Gandara D. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021 10; 16(10):1647-1662. PMID: 34246791.
    Citations: 14     Fields:    Translation:Humans
  10. Lin JJ, Choudhury NJ, Yoda S, Zhu VW, Johnson TW, Sakhtemani R, Dagogo-Jack I, Digumarthy SR, Lee C, Do A, Peterson J, Prutisto-Chang K, Malik W, Hubbeling HG, Langenbucher A, Schoenfeld AJ, Falcon CJ, Temel JS, Sequist LV, Yeap BY, Lennerz JK, Shaw AT, Lawrence MS, Ou SI, Hata AN, Drilon A, Gainor JF. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. Clin Cancer Res. 2021 05 15; 27(10):2899-2909. PMID: 33685866.
    Citations: 5     Fields:    
  11. Dagogo-Jack I, Moonsamy P, Gainor JF, Lennerz JK, Piotrowska Z, Lin JJ, Lennes IT, Sequist LV, Shaw AT, Goodwin K, Stevens SE, Do A, Digumarthy SR, Price K, Muzikansky A, Hata AN, Heist RS. A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. J Thorac Oncol. 2021 05; 16(5):850-859. PMID: 33545388.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  12. Neal JW, Costa DB, Muzikansky A, Shrager JB, Lanuti M, Huang J, Ramachandran KJ, Rangachari D, Huberman MS, Piotrowska Z, Kris MG, Azzoli CG, Sequist LV, Chaft JE. Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2021 01; 5:325-332. PMID: 34151132.
    Citations: 1     Fields:    Translation:CTClinical Trials
  13. Sequist LV, Skates SJ, Haas W. A New Era of Protein-Based Assays for Cancer Early Detection. J Thorac Oncol. 2021 02; 16(2):191-193. PMID: 33494925.
    Citations:    Fields:    Translation:Humans
  14. White MN, Piotrowska Z, Stirling K, Liu SV, Banwait MK, Cunanan K, Sequist LV, Wakelee HA, Hausrath D, Neal JW. Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. Clin Lung Cancer. 2021 05; 22(3):201-209. PMID: 33610453.
    Citations: 4     Fields:    Translation:Humans
  15. Mendoza DP, Heeger A, Mino-Kenudson M, Lanuti M, Shepard JO, Sequist LV, Digumarthy SR. Clinicopathologic and Longitudinal Imaging Features of Lung Cancer Associated With Cystic Airspaces: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2021 02; 216(2):318-329. PMID: 32755209.
    Citations: 3     Fields:    Translation:Humans
  16. Wysota M, Asiry S, Goldstein Y, Sequist LV, Khader S, Halmos B. Revolving Door of Histologic Transformation-Tumor Heterogeneity Complicating the Management of EGFR-Mutated Lung Adenocarcinoma: A Case of Jekyll and Hyde. JTO Clin Res Rep. 2021 Feb; 2(2):100128. PMID: 34589988.
    Citations:    
  17. Sands J, Tammemägi MC, Couraud S, Baldwin DR, Borondy-Kitts A, Yankelevitz D, Lewis J, Grannis F, Kauczor HU, von Stackelberg O, Sequist L, Pastorino U, McKee B. Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation. J Thorac Oncol. 2021 01; 16(1):37-53. PMID: 33188913.
    Citations: 8     Fields:    Translation:HumansPHPublic Health
  18. Piper-Vallillo AJ, Mooradian MJ, Meador CB, Yeap BY, Peterson J, Sakhi M, Do A, Zubiri L, Stevens S, Vaughn J, Goodwin K, Gavralidis A, Willers H, Miller A, Farago A, Piotrowska Z, Lin JJ, Dagogo-Jack I, Lennes IT, Sequist LV, Temel JS, Heist RS, Digumarthy S, Reynolds KL, Gainor JF. Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations. JTO Clin Res Rep. 2021 Jan; 2(1):100124. PMID: 33205053.
    Citations: 2     
  19. Garrana SH, Dagogo-Jack I, Cobb R, Kuo AH, Mendoza DP, Zhang EW, Heeger A, Sequist LV, Digumarthy SR. Clinical and Imaging Features of Non-Small-Cell Lung Cancer in Young Patients. Clin Lung Cancer. 2021 01; 22(1):23-31. PMID: 33189594.
    Citations: 2     Fields:    Translation:Humans
  20. Awad MM, Gadgeel SM, Borghaei H, Patnaik A, Yang JC, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Altan M, Jalal SI, Panwalkar A, Gubens M, Sequist LV, Saraf S, Zhao B, Piperdi B, Langer CJ. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. J Thorac Oncol. 2021 01; 16(1):162-168. PMID: 33069888.
    Citations: 16     Fields:    Translation:Humans
  21. Lin JJ, Liu SV, McCoach CE, Zhu VW, Tan AC, Yoda S, Peterson J, Do A, Prutisto-Chang K, Dagogo-Jack I, Sequist LV, Wirth LJ, Lennerz JK, Hata AN, Mino-Kenudson M, Nardi V, Ou SI, Tan DS, Gainor JF. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol. 2020 12; 31(12):1725-1733. PMID: 33007380.
    Citations: 21     Fields:    Translation:Humans
  22. McClatchy DM, Willers H, Hata AN, Piotrowska Z, Sequist LV, Paganetti H, Grassberger C. Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction Period. Cancer Res. 2020 11 15; 80(22):5121-5133. PMID: 32907839.
    Citations: 2     Fields:    Translation:Humans
  23. Piper-Vallillo AJ, Sequist LV, Piotrowska Z. Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review. J Clin Oncol. 2020 Jun 18; JCO1903123. PMID: 32552277.
    Citations: 26     Fields:    
  24. Chiang AC, Sequist LVD, Gilbert J, Conkling P, Thompson D, Marcoux JP, Gettinger S, Kowanetz M, Molinero L, O'Hear C, Fassò M, Lam S, Gordon MS. Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer. Clin Lung Cancer. 2020 09; 21(5):455-463.e4. PMID: 32586767.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  25. Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, Huberman MS, Sequist LV, Kobayashi SS, Costa DB. Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res. 2020 May 01; 26(9):2277. PMID: 32358026.
    Citations:    Fields:    
  26. Chabon JJ, Hamilton EG, Kurtz DM, Esfahani MS, Moding EJ, Stehr H, Schroers-Martin J, Nabet BY, Chen B, Chaudhuri AA, Liu CL, Hui AB, Jin MC, Azad TD, Almanza D, Jeon YJ, Nesselbush MC, Co Ting Keh L, Bonilla RF, Yoo CH, Ko RB, Chen EL, Merriott DJ, Massion PP, Mansfield AS, Jen J, Ren HZ, Lin SH, Costantino CL, Burr R, Tibshirani R, Gambhir SS, Berry GJ, Jensen KC, West RB, Neal JW, Wakelee HA, Loo BW, Kunder CA, Leung AN, Lui NS, Berry MF, Shrager JB, Nair VS, Haber DA, Sequist LV, Alizadeh AA, Diehn M. Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020 04; 580(7802):245-251. PMID: 32269342.
    Citations: 75     Fields:    Translation:Humans
  27. Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JC, Lee JS, Su WC, Kowalski D, Orlov S, Cantarini M, Verheijen RB, Mellemgaard A, Ottesen L, Frewer P, Ou X, Oxnard G. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020 03; 21(3):373-386. PMID: 32027846.
    Citations: 69     Fields:    Translation:HumansCTClinical Trials
  28. Solomon BJ, Tan L, Lin JJ, Wong SQ, Hollizeck S, Ebata K, Tuch BB, Yoda S, Gainor JF, Sequist LV, Oxnard GR, Gautschi O, Drilon A, Subbiah V, Khoo C, Zhu EY, Nguyen M, Henry D, Condroski KR, Kolakowski GR, Gomez E, Ballard J, Metcalf AT, Blake JF, Dawson SJ, Blosser W, Stancato LF, Brandhuber BJ, Andrews S, Robinson BG, Rothenberg SM. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. J Thorac Oncol. 2020 04; 15(4):541-549. PMID: 31988000.
    Citations: 34     Fields:    Translation:Humans
  29. Tan DS, Leighl NB, Riely GJ, Yang JC, Sequist LV, Wolf J, Seto T, Felip E, Aix SP, Jonnaert M, Pan C, Tan EY, Ko J, Moody SE, Kim DW. Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. Lancet Respir Med. 2020 06; 8(6):561-572. PMID: 31954624.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  30. Bar-Sagi D, Knelson EH, Sequist LV. A bright future for KRAS inhibitors. Nat Cancer. 2020 01; 1(1):25-27. PMID: 35121842.
    Citations: 2     
  31. Mendoza DP, Lin JJ, Rooney MM, Chen T, Sequist LV, Shaw AT, Digumarthy SR. Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer. AJR Am J Roentgenol. 2020 04; 214(4):766-774. PMID: 31887093.
    Citations: 7     Fields:    Translation:Humans
  32. Roberts TJ, Lennes IT, Hawari S, Sequist LV, Park ER, Willers H, Frank A, Gaissert H, Shepard JA, Ryan D. Integrated, Multidisciplinary Management of Pulmonary Nodules Can Streamline Care and Improve Adherence to Recommendations. Oncologist. 2020 05; 25(5):431-437. PMID: 31876321.
    Citations: 3     Fields:    Translation:Humans
  33. Piper-Vallillo AJ, Sequist LV. Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib. JACC CardioOncol. 2019 Dec; 1(2):179-181. PMID: 34396180.
    Citations: 1     
  34. Dizier B, Callegaro A, Debois M, Dreno B, Hersey P, Gogas HJ, Kirkwood JM, Vansteenkiste JF, Sequist LV, Atanackovic D, Goeman J, van Houwelingen H, Salceda S, Wang F, Therasse P, Debruyne C, Spiessens B, Brichard VG, Louahed J, Ulloa-Montoya F. A Th1/IFN? Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 04 01; 26(7):1725-1735. PMID: 31732522.
    Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
  35. Digumarthy SR, Mendoza DP, Lin JJ, Chen T, Rooney MM, Chin E, Sequist LV, Lennerz JK, Gainor JF, Shaw AT. Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer. Clin Lung Cancer. 2020 03; 21(2):153-159.e3. PMID: 31708389.
    Citations: 8     Fields:    Translation:Humans
  36. Dagogo-Jack I, Piotrowska Z, Cobb R, Banwait M, Lennerz JK, Hata AN, Digumarthy SR, Sequist LV. Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion. J Thorac Oncol. 2019 10; 14(10):e226-e228. PMID: 31558234.
    Citations: 5     Fields:    Translation:Humans
  37. Digumarthy SR, Mendoza DP, Padole A, Chen T, Peterson PG, Piotrowska Z, Sequist LV. Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer. Cancers (Basel). 2019 Sep 13; 11(9). PMID: 31540242.
    Citations: 6